Business
Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer
Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer\n\n\n\n\n\nRegen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer\nPR Newswire\nSAN DIEGO, December 7, 2016\n\n\n\nSAN DIEGO, December 7, 2016 /PRNewswire/ --\n\nRegen BioPharma Inc. (OTCQB: RGBPP) In a recent study published in the International Journal of Molecular Sciences a team of scientists in Guangzhou, China[1] have demonstrated that expression of NR2F6 in patients with early cervical cancer correlates with poor prognoses.  These scientists tested for NR2F6 in patient's cervical cancer tissue as well as in the normal tissue surrounding each of their tumors.\n\n\"This is an interesting study and the first that I am aware of that has tested for NR2F6 in patients with cervical cancer,\" said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen BioPharma, Inc. \"What they found was that those patients who had high amounts of NR2F6 protein expressed in their tumors died much faster than those patients with low or no expression of NR2F6 protein.  To me, this is an important validation of the role of NR2F6 in cancer in humans, rather than simply animal models, and implies that inhibiting NR2F6 may be beneficial for these patients.  While the study didn't go into the mechanism of action, it did show clear correlation and statistical significance indicating that NR2F6 expression is a potential biomarker for early cervical cancer.\"\n\nRegen BioPharma, Inc. is developing small molecule inhibitors and activators of NR2F6.  Inhibitors (which inhibit the expression of NR2F6) are expected to be useful in the treatment of various cancers and activators (which activate the expression of NR2F6) in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.  \n\n\"This journal article provides empirical evidence that supports our belief that inhibiting NR2F6 is a key to treating cancer in patients,\" noted David Koos, Regen's Chairman & CEO.  \"Our company sees an opportunity to enhance both the longevity and quality of life through further developing its NR2F6 small molecule therapies for treating cancer and autoimmune diseases.\"  \n\nRegen is also party to an agreement whereby Zander Therapeutics, Inc. has been granted b...